July 18, 2024European Heart Journal85 citationsOpen Access
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial
Ver artículo completo
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Evidence is lacking that correcting iron deficiency (ID) has clinically important benefits for patients with heart failure with preserved ejection fraction (HFpEF).
Cite This Study
Haehling et al. (Thu,) studied this question.